Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders
Insulin resistance and other risk factors for atherosclerosis, such as hypertension and hypercholesterolemia, promote endothelial dysfunction and lead to development of metabolic syndrome which constitutes an introduction to cardiovascular disease. The insulin resistance and endothelial dysfunction...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/3634948 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555899993980928 |
|---|---|
| author | A. Janus E. Szahidewicz-Krupska G. Mazur A. Doroszko |
| author_facet | A. Janus E. Szahidewicz-Krupska G. Mazur A. Doroszko |
| author_sort | A. Janus |
| collection | DOAJ |
| description | Insulin resistance and other risk factors for atherosclerosis, such as hypertension and hypercholesterolemia, promote endothelial dysfunction and lead to development of metabolic syndrome which constitutes an introduction to cardiovascular disease. The insulin resistance and endothelial dysfunction cross talk between each other by numerous metabolic pathways. Hence, targeting one of these pathologies with pleiotropic treatment exerts beneficial effect on another one. Combined and expletive treatment of hypertension, lipid disorders, and insulin resistance with nonpharmacological interventions and conventional pharmacotherapy may inhibit the transformation of metabolic disturbances to fully developed cardiovascular disease. This paper summarises the common therapeutic targets for insulin resistance, endothelial dysfunction, and vascular inflammatory reaction at molecular level and analyses the potential pleiotropic effects of drugs used currently in management of cardiovascular disease, metabolic syndrome, and diabetes. |
| format | Article |
| id | doaj-art-06e0b338c2e14684aed6448669c1e79c |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-06e0b338c2e14684aed6448669c1e79c2025-02-03T05:46:54ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/36349483634948Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersA. Janus0E. Szahidewicz-Krupska1G. Mazur2A. Doroszko3Department of Internal Medicine, Occupational Diseases Hypertension and Clinical Oncology, Wroclaw Medical University, Ulica Borowska 213, 50-556 Wrocław, PolandDepartment of Internal Medicine, Occupational Diseases Hypertension and Clinical Oncology, Wroclaw Medical University, Ulica Borowska 213, 50-556 Wrocław, PolandDepartment of Internal Medicine, Occupational Diseases Hypertension and Clinical Oncology, Wroclaw Medical University, Ulica Borowska 213, 50-556 Wrocław, PolandDepartment of Internal Medicine, Occupational Diseases Hypertension and Clinical Oncology, Wroclaw Medical University, Ulica Borowska 213, 50-556 Wrocław, PolandInsulin resistance and other risk factors for atherosclerosis, such as hypertension and hypercholesterolemia, promote endothelial dysfunction and lead to development of metabolic syndrome which constitutes an introduction to cardiovascular disease. The insulin resistance and endothelial dysfunction cross talk between each other by numerous metabolic pathways. Hence, targeting one of these pathologies with pleiotropic treatment exerts beneficial effect on another one. Combined and expletive treatment of hypertension, lipid disorders, and insulin resistance with nonpharmacological interventions and conventional pharmacotherapy may inhibit the transformation of metabolic disturbances to fully developed cardiovascular disease. This paper summarises the common therapeutic targets for insulin resistance, endothelial dysfunction, and vascular inflammatory reaction at molecular level and analyses the potential pleiotropic effects of drugs used currently in management of cardiovascular disease, metabolic syndrome, and diabetes.http://dx.doi.org/10.1155/2016/3634948 |
| spellingShingle | A. Janus E. Szahidewicz-Krupska G. Mazur A. Doroszko Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders Mediators of Inflammation |
| title | Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders |
| title_full | Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders |
| title_fullStr | Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders |
| title_full_unstemmed | Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders |
| title_short | Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders |
| title_sort | insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders |
| url | http://dx.doi.org/10.1155/2016/3634948 |
| work_keys_str_mv | AT ajanus insulinresistanceandendothelialdysfunctionconstituteacommontherapeutictargetincardiometabolicdisorders AT eszahidewiczkrupska insulinresistanceandendothelialdysfunctionconstituteacommontherapeutictargetincardiometabolicdisorders AT gmazur insulinresistanceandendothelialdysfunctionconstituteacommontherapeutictargetincardiometabolicdisorders AT adoroszko insulinresistanceandendothelialdysfunctionconstituteacommontherapeutictargetincardiometabolicdisorders |